Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock


Buy Cypress Bioscience – Analyst Blog

Source: http://www.zacks.com/stock/news/16489/Buy+Cypress+Bioscience+-+Analyst+Blog
 Posted on Friday, December 19th, 2008 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -

With a data from a third positive phase III trial in fibromyalgia released in early December 2008, we are feeling confident that the FDA will approval Cypress Bioscience, Inc.’s (CYPR) and partner Forest Laboratories, Inc. (FRX) milnacipran product during the first quarter of 2009.

Approval of milnacipran will be a transformational event for Cypress. The company should become almost immediately profitable based on royalties from Forest Labs. By 2013 we see total revenues exceeding $110 million, with net margins above 50%.

We see fair value at $12 per share, or 25x our 2012 EPS estimate of $1.12 per share, discounted back to present day.

Read the full analyst report on CYPR

Read the full analyst report on FRX

“CYPR” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries
About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries

Leave a Reply

Name

Email (kept private)

Website









No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.